ArticleScientific reports2026
Hedyotis diffusa and Scutellaria barbata enhance the anti-ovarian cancer effect of cisplatin through network pharmacology analysis and molecular docking technology.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hedyotis diffusa Willd (HD) and Scutellaria barbata D.Don (SB) are widely used traditional Chinese herbs with detoxifying properties and anti-tumor activities. The HD-SB pairing demonstrated significant anti-tumor efficacy in cancer, however, the synergistic potential of HD-SB with cisplatin in the treatment of cancer remains poorly understood. The current work aimed to uncover the synergistic effect of HD-SB with cisplatin on ovarian cancer. In the present study, the combination of HD-SB and cisplatin exhibited a pronounced inhibitory effect on the proliferation, migration and invasion, while promoting effect on apoptosis of ovarian cancer cells. Moreover, the interaction between drug compounds and disease targets contained 277 nodes and 1395 edges, the highlighting active ingredients were quercetin, luteolin, wogonin. Among the PPI network, the top targets were TP53, STAT3, SRC, AKT1, HSP90AA1, ESR1, EGFR, TNF, PIK3R1, IL6, PIK3CA, PIK3CB. Furthermore, GO enrichemnt analysis revealed that the target intersection mainly involved in biological process, cellular component and molecular function, KEGG analysis revealed that the target intersection mainly contained the pathways in cancer, PI3K/AKT signaling pathway, proteoglycans in cancer, MAPK signaling pathway. Ultimately, the molecular docking revealed that quercetin, luteolin and wogonin exhibited significant affinity with AKT1 and PIK3CA. Mechanistically, HD-SB enhance the anti-tumor effect of cisplatin on ovarian cancer via PI3K/AKT pathway. Taken together, our study revealed that the combination of HD-SB exhibited an enhanced capacity to improve cisplatin sensitivity in ovarian cancer cells through the PI3K/AKT pathway. HD-SB in combination with cisplatin could be a potential therapeutic strategy for the treatment of ovarian cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.